Baijin Life Science Holdings Ltd
01466
Company Profile
Business description
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
Contact
66 Gloucester Road
Office B, 9/F Pico Tower
Wanchai
Hong Kong
HKGT: +852 36112188
Sector
Consumer Cyclical
Stock type
Cyclical
Industry
Luxury Goods
Fiscal Year End
31 March 2027
Employees
79
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,199.29 | 18.95 | -0.23% |
| DAX 40 | 24,616.22 | 142.83 | -0.58% |
| Dow JONES (US) | 50,921.55 | 54.77 | 0.11% |
| FTSE 100 | 10,373.20 | 5.15 | 0.05% |
| HKSE | 24,657.06 | 304.89 | -1.22% |
| NASDAQ | 26,072.92 | 363.48 | 1.41% |
| Nikkei 225 | 64,024.60 | 2,563.52 | -3.85% |
| NZX 50 Index | 13,038.24 | 123.73 | -0.94% |
| S&P 500 | 7,437.52 | 53.78 | 0.73% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 3,959.34 | 68.40 | -1.70% |